Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34989798.
- Also identified by DOI 10.1001/jamanetworkopen.2021.42531 and PMC identifier 8739765.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pandemic.
Medical subject headings
- Buprenorphine
- COVID-19
- Drug Prescriptions
- Opioid-Related Disorders
- Pandemics
- Practice Patterns, Physicians'
- Telemedicine